Corrigendum: The parallel tales of microvascular angina and heart failure with preserved ejection fraction: A paradigm shift (European Heart Journal (2016) DOI: 10.1093/eurheartj/ehw461);The parallel tales of microvascular angina and heart failure with preserved ejection fraction: A paradigmshift

European Heart Journal

Volumn 38, Issue 7, 2017, Pages 473-477

  Crea, Filippo ^a   Merz, C Noel Bairey ^b   Beltrame, John F ^c   Kaski, Juan Carlos ^d   Ogawa, Hisao ^e   Ong, Peter ^f   Sechtem, Udo ^f   Shimokawa, Hiroaki ^g   Camici, Paolo G ^h  

^a CATHOLIC UNIVERSITY   (Italy)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d ST GEORGE S HOSPITAL   (United Kingdom)

^e KUMAMOTO UNIVERSITY   (Japan)

^f ROBERT BOSCH HOSPITAL   (Germany)

^g TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NATRIURETIC FACTOR; SEX HORMONE;

ARTICLE; CLINICAL FEATURE; CLINICAL OUTCOME; DIAGNOSTIC PROCEDURE; DYSPNEA; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOTHESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYNDROME X; TREATMENT INDICATION; AGE; COMPLICATION; HEART FAILURE; HEART STROKE VOLUME; PHYSIOLOGY; RISK FACTOR; SEX FACTOR;

AGE FACTORS; HEART FAILURE; HUMANS; MICROVASCULAR ANGINA; RISK FACTORS; SEX FACTORS; STROKE VOLUME;

EID: 85016185877     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw601     Document Type: Erratum

References (34)

1. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;356:830-840.
2. Patel MR, Peterson ED, Dai D, Brennan M, Redberg RF, Anderson V, Brindis RG, Douglas PS. Low diagnostic yield of elective coronary angiography. N Engl J Med 2010;362:886-895.
3. Gulati M, Cooper-DeHoff RM, McClure C, Johnson BD, Shaw LJ, Handberg EM, Zineh I, Kelsey SF, Arnsdorf MF, Black HR, Pepine CJ, Merz CN. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: A report from the women's ischemia syndrome evaluation study and the St James women take heart project. Arch Intern Med 2009;169:843-850.
4. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC. Get With the Guidelines Scientific Advisory Committee and Investigators. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012;126:65-75.
5. Piro M, Della Bona R, Abbate A, Biasucci LM, Crea F. Sex-related differences in myocardial remodeling. J Am Coll Cardiol 2010;55:1057-1065.
6. Pries AR, Reglin R. Coronary microcirculatory pathophysiology: can we afford it to remain a black box? Eur Heart J 2017;38:478-488.
7. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013;62:263-271.
8. Lee JF, Barrett-O'keefe Z, Garten RS, Nelson AD, Ryan JJ, Nativi JN, Richardson RS, Wray DW. Evidence of microvascular dysfunction in heart failure with preserved ejection fraction. Heart 2016;102:278-284.
9. De Boer RA, Pinto YM, Van Veldhuisen DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: The role of microvascular growth and abnormalities. Microcirculation 2003;10:113-126.
10. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O'meara E, Desai AS, Heitner JF, Li G, Fang J, Rouleau J, Zile MR, Markov V, Ryabov V, Reis G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD. Cardiac structure and function in heart failure with preserved ejection fraction. Baseline findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2014;7:104-115.
11. Schulz E, Jansen T, Wenzel P, Daiber A, MüNzel T. Nitric oxide, tetrahydrobiopterin, oxidative stress and endothelial dysfunction in hypertension. Antioxid Redox Signal 2008;10:1115-1126.
12. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 2015;131:550-559.
13. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002;106: 130-135.
14. Vettel C, Lammle S, Ewens S, Cervirgen C, Emons J, Ongherth A, Dewenter M, Lindner D, Westermann D, Nikolaev VO, Lutz S, Zimmermann WH, El-Armouche A. PDE2-mediated cAMP hydrolysis accelerates cardiac fibroblast to myofibroblast conversion and is antagonized by exogenous activation of cGMP signaling pathways. Am J Physiol Heart Circ Physiol 2014;306:H1246-H1252.
15. O'riordan E, Mendelev N, Patschan S, Patschan D, Eskander J, Cohen-Gould L, Chander P, Goligorsky MS. Chronic NOS inhibition actuates endothelialmesenchymal transformation. Am J Physiol Heart Circ Physiol 2007;292:H285-H294.
16. Ong P, Athanasiadis A, Borgulya G, Mahrholdt H, Kaski JC, Sechtem U. High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronaryVAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol 2013;59:655-662.
17. Arrebola-Moreno AL, Arrebola JP, Moral-Ruiz A, Ramirez-Hernandez JA, Melgares-Moreno R, Kaski JC. Coronary microvascular spasm triggers transient ischemic left ventricular diastolic abnormalities in patients with chest pain and angiographically normal coronary arteries. Atherosclerosis 2014; 236:207e-214e.
18. Shimokawa H. 2014 Williams Harvey Lecture: importance of coronary vasomotion abnormalities-from bench to bedside. Eur Heart J 2014;35:3180-3193.
19. Lanza GA, Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation 2010;121:2317-2325.
20. Crea F, Lanza GA. Treatment of microvascular angina: The need for precision medicine. Eur Heart J 2016; pii: ehw021.
21. Reilkoff RA, Bucala R, Herzog EL. Fibrocytes: emerging effector cells in chronic inflammation. Nat Rev Immunol 2011;11:427-435.
22. Pilling D, Buckley CD, Salmon M, Gomer RH. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol 2003;171:5537-5546.
23. Li P, Wang D, Lucas J, Oparil S, Xing D, Cao X, Novak L, Renfrow MB, Chen Y. Atrial natriuretic peptide inhibits transforming growth factor-induced smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res 2008;102:185-192.
24. Pepine CJ, Petersen JW, Bairey Merz CN. A microvascular-myocardial diastolic dysfunctional state and risk for mental stress ischemia. A revised concept of ischemia during daily life. JACC Cardiov Imaging 2014;7:362-365.
25. Ikonomidis I, Tzortis S, Triantafyllidi H, Parissis Parissis J, Papadopoulos C, Venetsanou K, Trivilou P, Paraskevaidis I, Lekakis J. Association of impaired left ventricular twisting-untwisting with vascular dysfunction, neurohormonal activation and impaired exercise capacity in hypertensive heart disease. Eur J Heart Fail 2015;17:1240-1251.
26. Tschope C, Post H. Latent ischemia as a trigger for a circulus vitioses of inflammation, fibrosis and stiffness in HFpEF [Editorial]. Eur J Heart Fail 2015;17: 1210-1212.
27. Silverman MG, Patel B, Blankstein R, Lima JAC, Blumenthal RS, Khurram Nasir K, Blaha MJ. Impact of race, ethnicity, and multimodality biomarkers on the incidence of new-onset heart failure with preserved ejection fraction (from the multi-ethnic study of atherosclerosis). Am J Cardiol 2016;117:1474e-1481e.
28. Srivaratharajah K, Coutinho T, deKemp R, Liu P, Haddad H, Stadnick E, Davies RA, Chih S, Dwivedi G, Guo A, Wells GA, Bernick J, Beanlands R, Mielniczuk LM. Reduced myocardial flow in heart failure patients with preserved ejection fraction. Circ Heart Fail 2016;9:pii: e002562. doi:10.1161/CIRCHEARTFAILURE.115.002562.
29. Fukui S, Fukumoto Y, Suzuki J, Saji K, Nawata J, Tawara S, Shinozaki T, Kagaya Y, Shimokawa H. Long-term inhibition of Rho-kinase ameliorates diastolic heart failure in hypertensive rats. J Cardiovasc Pharmacol 2008;51:317-326.
30. Crea F, Camici PG, Bairey Merz CN. Coronary microvascular dysfunction: an update. Eur Heart J 2014;35:1101-1111.
31. Richards AM, Januzzi JL, Jr, Troughton RW. Natriuretic peptides in heart failure with preserved ejection fraction. Heart Fail Clin 2014;10:453-470.
32. Shah KS, Maisel AS. Novel biomarkers in heart failure with preserved ejection fraction. Heart Fail Clin 2014;10:471-479.
33. Dean J, Deal Cruz Sherwin Mehta PK, Bairey Merz CN. Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy. Nat Rev Cardiol 2015; 12:406-414.
34. Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, Shah SJ, Ahmed A, Bonow RO, Cleland JG, Cody RJ, Chioncel O, Collins SP, Dunnmon P, Filippatos G, Lefkowitz MP, Marti CN, McMurray JJ, Misselwitz F, Nodari S, O'connor C, Pfeffer MA, Pieske B, Pitt B, Rosano G, Sabbah HN, Senni M, Solomon SD, Stockbridge N, Teerlink JR, Georgiopoulou VV, Gheorghiade M. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail 2014;2:97-112.